Mouse models for immuno-oncology.
Document Type
Article
Publication Date
7-1-2023
Original Citation
Bosenberg M,
Liu E,
Yu CI,
Palucka K.
Mouse models for immuno-oncology. Trends Cancer. 2023;9(7):578-90.
Keywords
JMG, JGM, Animals, Mice, Neoplasms, Medical Oncology, Disease Models, Animal, Translational Research, Biomedical, Immunotherapy
JAX Source
Trends Cancer. 2023;9(7):578-90.
ISSN
2405-8025
PMID
37087398
DOI
https://doi.org/10.1016/j.trecan.2023.03.009
Grant
KP and CY: R01 CA21988, and P30 CA034196-34; EL: Mark Foundation Cancer Fund, 19-036-ASP; and P30 CA034196- 34; MB: P50 CA121974, U01 CA233096, and U01 CA238728.
Abstract
Realizing the clinical promise of cancer immunotherapy is hindered by gaps in our knowledge of in vivo mechanisms underlying treatment response as well as treatment limiting toxicity. Preclinical in vivo model systems and technologies are required to address these knowledge gaps and to surmount the challenges faced in the clinical application of immunotherapy. Mice are commonly used for basic and translational research to support development and testing of immune interventions, including for cancer. Here, we discuss the advantages and the limitations of current models as well as future developments.